8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Apr 10, 2026·SEC
Material company update
Apr 10, 2026·SEC
BiomX Inc.(PHGE)Earnings, Financials & Key Ratios
PHGE•AMEX
$0.62
$1.01B mkt cap·Price updated May 7, 2026
AboutBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Show more
- Revenue$0
- EBITDA-$30M+19.4%
- Net Income-$36M-104.2%
- EPS (Diluted)-22.19+20.6%
- ROE-316.9%-143.4%
- ROIC-444.85%-45.8%
- Interest Coverage-33.45-138.8%
PHGE Key Insights
BiomX Inc. (PHGE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PHGE Price & Volume
BiomX Inc. (PHGE) stock price & volume — 10-year historical chart
Loading chart...
PHGE Growth Metrics
BiomX Inc. (PHGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-62.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM95.97%
Return on Capital
10 Years-69.01%
5 Years-88.14%
3 Years-111.37%
Last Year-66.6%
PHGE Recent Earnings
BiomX Inc. (PHGE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 24, 2026EPS
$4.61
Est $4.61
+0.0%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$5.51
Est $6.08
+9.4%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.19
Est $0.33
+157.6%
Revenue
—
Q2 2025
May 15, 2025EPS
$0.33
Est $0.42
+21.4%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $4.61vs $4.61+0.0% | — |
| Q4 2025 | Nov 12, 2025 | $5.51vs $6.08+9.4% | — |
| Q3 2025 | Aug 13, 2025 | $0.19vs $0.33+157.6% | — |
| Q2 2025 | May 15, 2025 | $0.33vs $0.42+21.4% | — |
Based on last 12 quarters of dataView full earnings history →
PHGE Peer Comparison
BiomX Inc. (PHGE) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LSTA | 29.41M | 3.23 | -1.69 | -83% | -97.56% | -85.5% | ||
 ASMB | 491.56M | 30.93 | -56.24 | 153.52% | -10.15% | -4.21% | 0.01 | |
 ACXP | 4.98M | 2.12 | -0.40 | -6.04% | ||||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare PHGE vs Peers
BiomX Inc. (PHGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHGE Income Statement
BiomX Inc. (PHGE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 95K | 210K | 0 | 0 | 0 | 0 | 871K | 1.8M | 2.92M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -95K▲ 0% | -210K▼ 121.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -871K▲ 0% | -1.8M▼ 107.0% | -2.92M▼ 62.1% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -121.05% | 100% | - | - | - | - | -107% | -62.06% |
| Operating Expenses | 7.28M | 12.93M | 22.21M | 30.26M | 35.46M | 27.22M | 26.81M | 37.22M | 30.92M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.54M | 3.36M | 8.72M | 9.99M | 11.27M | 9.46M | 7.78M | 11.78M | 9.63M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 4.74M | 9.57M | 13.96M | 21.61M | 22.68M | 16.24M | 19.04M | 24.66M | 21.29M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -466K | -1.34M | 1.52M | 1.52M | 0 | 785K | 0 |
| Operating Income | -7.37M▲ 0% | -13.14M▼ 78.3% | -22.21M▼ 69.0% | -30.26M▼ 36.3% | -35.46M▼ 17.2% | -27.22M▲ 23.2% | -27.68M▼ 1.7% | -39.03M▼ 41.0% | -32.91M▲ 15.7% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -78.26% | -68.99% | -36.25% | -17.2% | 23.24% | -1.71% | -40.97% | 15.67% |
| EBITDA | -7.28M | -12.93M | -21.89M | -29.6M | -32.9M | -24.7M | -26.81M | -37.22M | -29.99M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -77.7% | -69.28% | -35.21% | -11.15% | 24.92% | -8.56% | -38.82% | 19.44% |
| D&A (Non-Cash Add-back) | 95K | 210K | 318K | 662K | 2.56M | 2.52M | 871K | 1.8M | 2.92M |
| EBIT | -6.43M | -12.72M | -22.21M | -30.26M | -35.46M | -26.18M | -23.69M | -14.93M | -35.21M |
| Net Interest Income | 0 | 0 | 857K | 634K | -697K | -1.17M | -1.28M | -1.74M | -524K |
| Interest Income | -21K | 0 | 921K | 641K | 2K | 902K | 1.12M | 1.05M | 460K |
| Interest Expense | 0 | 0 | 64K | 7K | 699K | 2.07M | 2.4M | 2.79M | 984K |
| Other Income/Expense | 939K | 421K | 1.64M | 172K | -697K | -1.03M | 1.54M | 21.31M | -3.28M |
| Pretax Income | -6.43M▲ 0% | -12.72M▼ 97.7% | -20.56M▼ 61.7% | -30.09M▼ 46.3% | -36.16M▼ 20.2% | -28.25M▲ 21.9% | -26.15M▲ 7.5% | -17.71M▲ 32.2% | -36.19M▼ 104.3% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 67K | 65K | 23K | 13K | 7K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.19% | -0.23% | -0.09% | -0.07% | -0.02% |
| Net Income | -6.43M▲ 0% | -12.72M▼ 97.7% | -20.56M▼ 61.7% | -30.09M▼ 46.3% | -36.23M▼ 20.4% | -28.32M▲ 21.8% | -26.17M▲ 7.6% | -17.73M▲ 32.3% | -36.2M▼ 104.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -97.73% | -61.66% | -46.31% | -20.41% | 21.83% | 7.59% | 32.26% | -104.2% |
| Net Income (Continuing) | -6.43M | -12.72M | -20.56M | -30.09M | -36.23M | -28.32M | -26.17M | -17.73M | -36.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -62.13▲ 0% | -122.74▼ 97.6% | -15.96▲ 87.0% | -24.70▼ 54.8% | -264.67▼ 971.5% | -180.31▲ 31.9% | -96.90▲ 46.3% | -27.93▲ 71.2% | -22.19▲ 20.6% |
| EPS Growth % | - | -97.55% | 87% | -54.76% | -971.54% | 31.87% | 46.26% | 71.18% | 20.55% |
| EPS (Basic) | -62.13 | -122.74 | -15.96 | -24.70 | -264.67 | -180.31 | -96.90 | -27.93 | -22.19 |
| Diluted Shares Outstanding | 1.04M | 1.05M | 1.19M | 1.21M | 1.37M | 1.57M | 2.7M | 691.48M | 1.63B |
| Basic Shares Outstanding | 1.04M | 1.05M | 1.19M | 1.21M | 1.37M | 1.57M | 2.7M | 3.67M | 69.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PHGE Balance Sheet
BiomX Inc. (PHGE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.47M | 39.89M | 84.53M | 60.67M | 66.64M | 36.88M | 17.63M | 20.52M | 5.58M |
| Cash & Short-Term Investments | 8.15M | 39.66M | 82.41M | 56.33M | 62.1M | 33.33M | 14.91M | 17.81M | 4.96M |
| Cash Only | 6.99M | 8.6M | 72.41M | 36.48M | 62.1M | 31.33M | 14.91M | 17.81M | 4.96M |
| Short-Term Investments | 1.15M | 31.05M | 10M | 19.85M | 0 | 2M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 244K | 0 | 888K | 567K | 574K | 1.17M | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | -29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 50K | 2.25M | 1.4M | 1.49M | 1.52M | 254K | 620K |
| Total Non-Current Assets | 5.52M | 5.44M | 7.59M | 9.7M | 11.35M | 8.65M | 7.4M | 22.71M | 64.66M |
| Property, Plant & Equipment | 960K | 887K | 3.03M | 6.66M | 9.83M | 8.65M | 7.4M | 10.5M | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 4.56M | 4.56M | 3.04M | 1.52M | 0 | 0 | 12.05M | 208K |
| Long-Term Investments | 0 | 70.88M | 0 | 0 | 0 | 0 | 0 | 161K | 0 |
| Other Non-Current Assets | 4.56M | -70.88M | 5K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 13.99M▲ 0% | 45.33M▲ 224.0% | 92.12M▲ 103.2% | 70.36M▼ 23.6% | 77.99M▲ 10.8% | 45.53M▼ 41.6% | 25.03M▼ 45.0% | 43.23M▲ 72.7% | 70.24M▲ 62.5% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | - | 224.02% | 103.22% | -23.62% | 10.84% | -41.62% | -45.03% | 72.73% | 62.47% |
| Total Current Liabilities | 1.46M | 1.64M | 6.22M | 7.16M | 11.04M | 7.94M | 11.18M | 8.27M | 6.38M |
| Accounts Payable | 1K | 56.58K | 3.25M | 2.32M | 2.79M | 820K | 1.38M | 1.88M | 3.12M |
| Days Payables Outstanding | 3.84 | 98.34 | - | - | - | - | 578.72 | 380.99 | 389.73 |
| Short-Term Debt | 40K | 0 | 375K | 0 | 0 | 4.28M | 5.79M | 0 | 1.44M |
| Deferred Revenue (Current) | -40K | 58K | 60K | 65K | 1.98M | 242K | 28K | 0 | 0 |
| Other Current Liabilities | 1.42M | 581K | 756K | 0 | 0 | 0 | -28K | 1.48M | 1.82M |
| Current Ratio | 5.81x | 24.34x | 13.58x | 8.47x | 6.03x | 4.65x | 1.58x | 2.48x | 0.87x |
| Quick Ratio | 5.81x | 24.35x | 13.58x | 8.47x | 6.03x | 4.65x | 1.58x | 2.48x | 0.87x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1M | 889K | 1.44M | 5.73M | 19.41M | 16.55M | 10.77M | 10.82M | 706K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 14.41M | 10.59M | 5.4M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 856K | 5.03M | 4.79M | 3.8M | 3.24M | 8.45M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1M | 889K | 585K | 701K | 215K | 188K | 155K | 2.36M | 706K |
| Total Liabilities | 2.46M | 2.53M | 7.67M | 12.89M | 30.45M | 24.49M | 21.95M | 19.09M | 71.54M |
| Total Debt | 40K | 0 | 1.23M | 5.89M | 20.02M | 19.36M | 15.09M | 9.58M | 1.44M |
| Net Debt | -6.95M | -8.6M | -71.18M | -30.58M | -42.08M | -11.97M | 185K | -8.23M | -3.52M |
| Debt / Equity | 0.00x | - | 0.01x | 0.10x | 0.42x | 0.92x | 4.90x | 0.40x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -346.98x | -4322.57x | -50.73x | -13.16x | -11.52x | -14.01x | -33.45x |
| Total Equity | 11.53M▲ 0% | 42.8M▲ 271.2% | 84.46M▲ 97.3% | 57.47M▼ 32.0% | 47.53M▼ 17.3% | 21.04M▼ 55.7% | 3.08M▼ 85.4% | 24.15M▲ 683.8% | -1.3M▼ 105.4% |
| Equity Growth % | - | 271.23% | 97.31% | -31.95% | -17.29% | -55.74% | -85.36% | 683.77% | -105.39% |
| Book Value per Share | 11.13 | 40.62 | 70.91 | 47.35 | 34.72 | 13.39 | 1.14 | 0.03 | -0.00 |
| Total Shareholders' Equity | 11.53M | 42.8M | 84.46M | 57.47M | 47.53M | 21.04M | 3.08M | 24.15M | -1.3M |
| Common Stock | 201 | 65.75M | 2K | 2K | 2K | 2K | 3K | 6K | 7K |
| Retained Earnings | -8.89M | -21.61M | -42.17M | -72.26M | -108.48M | -136.8M | -162.97M | -180.7M | -216.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.02K | -21.61M | 0 | -72.26M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHGE Cash Flow Statement
BiomX Inc. (PHGE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.1M | -11.3M | -17.58M | -24.45M | -27.57M | -29.09M | -21.29M | -36.98M | -26.39M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -175.71% | -55.49% | -39.09% | -12.79% | -5.51% | 26.83% | -73.72% | 28.64% |
| Net Income | -6.43M | -12.72M | -20.56M | -30.09M | -36.23M | -28.32M | -26.17M | -17.73M | -36.2M |
| Depreciation & Amortization | 95K | 210K | 318K | 2.18M | 2.56M | 2.52M | 871K | 1.8M | 2.92M |
| Stock-Based Compensation | 0 | 0 | 938K | 2.89M | 3.24M | 1.53M | 1.06M | 1.85M | 2.09M |
| Deferred Taxes | 0 | -1.22K | 0 | 0 | 24K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.32M | -112K | -304K | 116K | -276K | -396K | 477K | -19.91M | 4.82M |
| Working Capital Changes | 928K | 367K | 2.03M | 453K | 3.1M | -4.43M | 2.48M | -2.99M | -23K |
| Change in Receivables | -225K | 187K | -100K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 407K | -228K | 3.06M | -858K | 427K | -1.98M | 556K | -3.17M | 1.24M |
| Cash from Investing | -2.12M | -30.04M | 19.74M | -10.86M | 16.17M | -2.11M | 1.95M | 715K | 108K |
| Capital Expenditures | -850K | -137K | -1.31M | -1.01M | -3.68M | -112K | -50K | -30K | -2K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | -112K | 0 | 0 | 0 | 4K | 0 | 0 | 663K | 110K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -29.9M | 21.05M | 0 | 4K | 5K | 1K | 82K | 0 |
| Cash from Financing | 12.95M | 43.04M | 61.55M | 134K | 37.28M | 292K | 2.9M | 38.37M | 13.19M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 14.22M | 0 | -4.25M | -10.75M | 0 |
| Equity Issued (Net) | 12.95M | 43.04M | 3.58M | -98K | 22.93M | 273K | 7.49M | 21.29M | 13.19M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -19K | -98K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 57.97M | 232K | 130K | 19K | -333K | 27.83M | 0 |
| Net Change in Cash | 6.74M▲ 0% | 1.7M▼ 74.8% | 63.72M▲ 3648.1% | -35.17M▼ 155.2% | 25.86M▲ 173.5% | -30.8M▼ 219.1% | -16.43M▲ 46.7% | 2.11M▲ 112.8% | -13.02M▼ 716.8% |
| Free Cash Flow | -4.95M▲ 0% | -11.44M▼ 131.1% | -18.89M▼ 65.1% | -25.46M▼ 34.8% | -31.25M▼ 22.8% | -29.2M▲ 6.6% | -21.34M▲ 26.9% | -37.01M▼ 73.5% | -26.39M▲ 28.7% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -131.13% | -65.1% | -34.77% | -22.78% | 6.56% | 26.94% | -73.46% | 28.69% |
| FCF per Share | -4.78 | -10.86 | -15.86 | -20.97 | -22.83 | -18.59 | -7.90 | -0.05 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.89x | 0.85x | 0.81x | 0.76x | 1.03x | 0.81x | 2.09x | 0.73x |
| Interest Paid | 0 | 0 | 0 | 0 | 67K | 1.55M | 1.87M | 1.44M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 399K | 65K | 54K | 13K | 0 |
PHGE Key Ratios
BiomX Inc. (PHGE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.79% | -46.82% | -32.32% | -42.4% | -69% | -82.59% | -216.99% | -130.21% | -316.9% |
| Return on Invested Capital (ROIC) | - | -50.83% | -70.16% | -113% | -164.49% | -281.25% | -336.77% | -305.15% | -444.85% |
| Debt / Equity | 0.00x | - | 0.01x | 0.10x | 0.42x | 0.92x | 4.90x | 0.40x | - |
| Interest Coverage | - | - | -346.98x | -4322.57x | -50.73x | -13.16x | -11.52x | -14.01x | -33.45x |
| FCF Conversion | 0.64x | 0.89x | 0.85x | 0.81x | 0.76x | 1.03x | 0.81x | 2.09x | 0.73x |
PHGE SEC Filings & Documents
BiomX Inc. (PHGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
PHGE Frequently Asked Questions
BiomX Inc. (PHGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BiomX Inc. (PHGE) grew revenue by 0.0% over the past year. Growth has been modest.
BiomX Inc. (PHGE) reported a net loss of $36.2M for fiscal year 2025.
Dividend & Returns
BiomX Inc. (PHGE) has a return on equity (ROE) of -316.9%. Negative ROE indicates the company is unprofitable.
BiomX Inc. (PHGE) had negative free cash flow of $26.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More PHGE
BiomX Inc. (PHGE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates